Stay updated on Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.

Latest updates to the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference3%

- Check27 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; the core identifier on the page has changed to reflect a newer release.SummaryDifference0.1%

- Check41 days agoChange DetectedVersion bumped from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.SummaryDifference0.2%

- Check48 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.2%

- Check56 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as new related topics on stomach and gastrointestinal diseases. However, several previous location details and specific disease resources have been removed.SummaryDifference2%

- Check70 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%

Stay in the know with updates to Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.